Evidence map›Paper›PMID 40083014›Full record

ReviewClinical epigenetics2025

Epigenetic regulatory protein chromobox family regulates multiple signalling pathways and mechanisms in cancer.

Weiyu Su, Weiwen Wang, Guanghui Zhang, Lianhe Yang

Abstract readReview
In one paragraph

Review in Clinical epigenetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Weiyu SuMedical College, Henan University of Chinese Medicine, Zhengzhou, 450046, Henan Province, China.
Weiwen WangMedical College, Henan University of Chinese Medicine, Zhengzhou, 450046, Henan Province, China.
Guanghui ZhangMedical College, Henan University of Chinese Medicine, Zhengzhou, 450046, Henan Province, China. zhangguanghui@hactcm.edu.cn.
Lianhe YangMedical College, Henan University of Chinese Medicine, Zhengzhou, 450046, Henan Province, China. 13598420711@139.com.

Funding

Henan University of Traditional Chinese Medicine, China 2023KYCX084
6 · The paper itself

Abstract

Signal transduction plays a pivotal role in modulating a myriad of critical processes, including the tumour microenvironment (TME), cell cycle arrest, proliferation and apoptosis of tumour cells, as well as their migration, invasion, and the epithelial-mesenchymal transition (EMT). Epigenetic mechanisms are instrumental in the genesis and progression of tumours. The Chromobox (CBX) family proteins, which serve as significant epigenetic regulators, exhibit tumour-specific expression patterns and biological functionalities. These proteins are influenced by a multitude of factors and could modulate the activation of diverse signalling pathways within tumour cells through alterations in epigenetic modifications, thereby acting as either oncogenic agents or tumour suppressors. This review aims to succinctly delineate the composition, structure, function, and expression of CBXs within tumour cells, with an emphasis on synthesizing and deliberating the CBXs-mediated activation of intracellular signalling pathways and the intricate mechanisms governing tumourigenesis and progression. Moreover, a plethora of contemporary studies have substantiated that CBXs might represent a promising target for the diagnosis and therapeutic intervention of tumour patients. We have also compiled and scrutinized the current research landscape concerning inhibitors targeting CBXs, aspiring to aid researchers in gaining a deeper comprehension of the biological roles and mechanisms of CBXs in the malignant evolution of tumours, and to furnish novel perspectives for the innovation of targeted tumour therapeutics.

Indexed as

Epigenesis, GeneticNeoplasmsPolycomb-Group ProteinsEpithelial-Mesenchymal TransitionGene Expression Regulation, NeoplasticHumansSignal TransductionTumor MicroenvironmentPolycomb-Group ProteinsChromobox family proteinsEpigenetic mechanismsTumour prognostic markerTumour signalling pathwaysTumour targeted therapy

Identifiers

PMID40083014
PMCPMC11907984

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.